Application of the Hedgehog pathway inhibitor in treatment fibrotic disease
WO2017167251A1
Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione
AU2016239141A1
Solid pharmaceutical formulation of PARP inhibitors and the use thereof
CN103570625A
N-(3-aryl-heteroaryl)-4-aryl-aryl carboxamide and analog as hedgehog pathway inhibitors and application thereof
CN104066723A
1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
WO2013013614A1
4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
WO2012159565A1
6-(aryl-carboxamide) imidazo [1,2-a] pyrimidine and 6-(aryl carboxamide) [1,2,4] triazolo [4,3-a] pyrimidine as hedgehog pathway inhibitor and use thereof
TW201245161A
1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof
CN103370316A
3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines as inhibitors of cell proliferation and the use thereof
CN102020648A
3-aryl-6-aryl-[1,2,4] triazol [4,3-b] pyridazine taken as cell proliferation inhibitor and application of cell proliferation inhibitor
WO2012065297A1
3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF